Clinical trial

Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

NCT01929200

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2013-08-01

PhasePHASE2

Study timeline

Study start (unknown)2013-08-01Date precision: month

Registry last updated2015-05-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small-cell Lung Cancerunresolved

Interventions

1-year treatment with icotinibDRUG

2-year treatment with icotinibDRUG

Sponsors & collaborators

Betta Pharmaceuticals Co., Ltd.lead sponsor

Mapped research locations

BeijingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01929200 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.